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Abstracts
Background Enhanced recovery after surgery (ERAS) protocols are evidence-based, multimodal and patient-centred approach to
optimize patient care and experience during their perioperative pathway. It has been shown to be effective in reducing length of
hospital stay and improving clinical outcomes. However, evidence on its effective in liver surgery remains weak. The aim of this
review is to investigate clinical benefits, cost-effectiveness and compliance to ERAS protocols in liver surgery.
Methods A systematic literature search was conducted using CINAHL Plus, EMBASE, MEDLINE, PubMed and Cochrane for
randomized control trials (RCTs) and cohort studies published between 2008 and 2019, comparing effect of ERAS protocols and
standard care on hospital cost, LOS, complications, readmission, mortality and compliance.
Results The search resulted in 6 RCTs and 21 cohort studies of 3739 patients (1777 in ERAS and 1962 in standard care group).
LOS was reduced by 2.22 days in ERAS group (MD = −2.22; CI, −2.77 to −1.68; p < 0.00001) compared to the standard care
group. Fewer patients in ERAS group experienced complications (RR, 0.71; 95% CI, 0.65–0.77; p = < 0.00001). Hospital cost
was significantly lower in the ERAS group (SMD= −0.98; CI, −1.37 to – 0.58; p < 0.0001).
Conclusion Our review concluded that the introduction of ERAS protocols is safe and feasible in hepatectomies, without
increasing mortality and readmission rates, whilst reducing LOS and risk of complications, and with a significant hospital cost
savings. Laparoscopic approach may be necessary to reduce complication rates in liver surgery. However, further studies are
needed to investigate overall compliance to ERAS protocols and its impact on clinical outcomes.
Keywords Enhanced recovery after surgery . Liver surgery . Systematic review andmeta-analysis
Introduction
The concept of developing a ‘multimodal approach’ to accel-
erate recovery and rehabilitation after surgery was first devel-
oped by Kehlet.1 This approach later evolved into what is now
known as enhanced recovery after surgery (ERAS). ERAS
protocols have been implemented in various surgical special-
ties especially colorectal surgery from the early 2000s.
However, due to patient safety concerns and high complica-
tion rates, the first cases of ERAS protocols in liver surgery
only appeared in the scientific journals in 2008.2, 3
The ERAS programme is an evidence-based, multimodal
and patient-centred approach to optimize patient care and ex-
perience during perioperative care.4 In 2016, the ERAS
Society published its first guideline for perioperative care in
liver surgery to add to existing ERAS guidelines regarding
other surgical specialities.5 This particular guideline consists
of 23 items including preoperative counselling, preoperative
carbohydrate loading, perioperative nutrition, avoidance of
bowel preparation, no routine use of surgical drain, thrombo-
embolism prophylaxis, antibiotic prophylaxis, minimally in-
vasive approach, intraoperative fluid restriction, multimodal
analgesia, prevention of hypothermia, early oral fluid and nor-
mal diet intake, glycaemic control, prevention of delayed gas-
tric emptying, stimulation of bowel movement, early mobili-
zation, prevention of postoperative nausea and vomiting, fluid
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management and systematic audit. Majority of the recommen-
dations were based on evidence from colorectal surgery due to
limited evidence in liver surgery. With entirely different pa-
tient cohorts between colorectal and liver surgery, their differ-
ent morbidities and therefore physiological stress on patients,
it is questionable whether ERAS principles used in colorectal
surgery can be truly extrapolated to liver surgery.
Traditionally, liver surgery is known to be associated with
high complication and mortality rates.6 With recent advance-
ment in surgical techniques and improvement in perioperative
care management, a mortality rate of less than 5% is now
achievable.7 Moreover, several reviews concluded that the
implementation of ERAS protocols is associated with a sig-
nificant reduction in length of hospital stay and postoperative
complications without increasing mortality and readmission
rates.7–14 However, evidence on cost-effectiveness and com-
pliance to ERAS protocols in liver surgery is limited. Two
previous meta-analyses have demonstrated a significant re-
duction in hospital expenditure following implementation of
ERAS protocols in liver surgery.9, 10 The conclusion reached
by these reviews was either based on low-quality RCTs and
cohort studies without conducting a separate meta-analysis of
RCTs and cohort studies. Furthermore, to date, no review has
investigated overall protocol compliance which is a key factor
to delivering a successful implementation of ERAS protocols.
The aim of this review is to investigate clinical benefits, cost-
effectiveness and compliance to ERAS protocols in liver
surgery.
Method
Search Strategy
This review was conducted in accordance with PRISMA
(preferred reporting items for systematic reviews and meta-
analyses) guidelines for meta-analysis.15 A systematic search
was conducted in March 2019 on the following database:
CINAHL Plus, EMBASE, MEDLINE, PubMed and
Cochrane for studies published between 2008 and 2019. The
search was limited to English language. Reference lists of
relevant RCTs and systematic reviews were searched for eli-
gible studies. The search terms such as ‘enhanced recovery’,
‘fast track’, ‘ERAS’, ‘perioperative care’, ‘enhanced rehabili-
tation’, ‘liver resection’, ‘liver surgery’, ‘hepatic resection’,
‘hepatobiliary’, ‘HPB surgery’, ‘hepato-pancreato-biliary’
and ‘hepatectomy’ were applied using Boolean operator (OR
and AND).
Inclusion/Exclusion Criteria
RCTs and non-RCTs studies were eligible for inclusion if they
all meet the following criteria, (1) studies of adult patients
undergoing liver surgery, (2) compared ERAS to standard care
and (3) report on at least one of the following outcomes:
length of hospital stay (LOS), complication rate, hospital cost,
readmission rates and mortality rates. Studies were excluded if
they were non-elective or transplant patients, non-English and
not comparing ERAS to standard care.
Data Extraction
All potential studies and relevant data were retrieved and ex-
tracted by one author (LN). Data were extracted using a data
extraction sheet agreed by all reviewers, and data extraction
was subsequently validated by other authors. Data extracted
included authors’ first and last names, study design, patient’
characteristics (ASA grade, age and sex), type of surgery,
outcomes measured, sample size, follow-up period and
ERAS programme items.
Literature Search
An initial search yielded 631 studies. Five hundred four ab-
stracts were screened after duplicates were removed. Four
hundred fifty ineligible articles identified through screening
were removed. Fifty-four full-text articles were assessed for
eligibility, of which 27 were excluded for the following rea-
sons: 1 study included both hepatic and pancreatic surgery, 11
cohort studies did not include standard care, 4 RCTs did not
include standard care, 1 paper related only to ERAS guide-
lines and 10 were reviews. The final 27 studies were included
in the meta-analysis (Fig. 1).
Outcomes of Interest
The primary outcome for this systematic review was hospital
cost. Secondary outcomes include LOS, complication rate,
readmission rates, mortality rates and compliance.
Quality Assessment
The quality of the RCTs was assessed in accordance with the
Cochrane Collaboration’s risk of bias tool16 (Fig. 2). The
Modified Downs and Black checklist was used for the assess-
ment of the methodological quality of both randomized and
non-randomized studies for both RCTs and non-RCTs.17 The
Modified Downs and Black checklist has a maximum of 28
points (11 points for reporting, 3 points for external validity, 7
points for internal validity – bias, 6 points for internal validity
– confounding (selection bias) and 1 point for power calcula-
tion (Table 1).
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Statistical Analysis
This meta-analysis was performed using Review Manager
(RevMan) version 5.3.43 Relative risk was used for all dichoto-
mous variables, weight mean difference or weight standardized
mean difference for continuous variable with 95% confidence
interval.44 Statistical significance level was set at p < 0.05.
Statistical heterogeneity was assessed using a chi-squared test
(χ2), I2 statistic, with p< 0.1 considered to be statistically signif-
icant. A fixed effect model was used for pooling. Where there is
significant evidence of heterogeneity (> 50%), random effect
model was used instead. Using themethod developed by devised
Hozo, Djulbegovic and Hozo (2005), study data presented as
medians and ranges or medians and interquartile ranges were
converted to mean and standard deviation (SD). Funnel plots
were used to assess presence of publication bias.
Results
Characteristics of Included Studies
A total of 3739 patients were included in the review (ranging
between 26 and 347 per study), 1777weremanaged according
to an ERAS protocol and 1962 according to standard periop-
erative care. The ERAS elements utilized in the studies range
between 8 and 23. A detailed list of ERAS elements utilized
by each study is shown in Table 2. Six studies were RCTs,22,
25, 28, 29, 32, 35 16 were case-control studies2, 18, 21, 23, 24, 27, 31,
Fig. 1 Flow chart of study
selection process
Fig. 2 Summary of risk of bias of RCTs
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33, 36–42 and five prospective studies.19, 20, 26, 30, 34 Eleven
studies included both open and laparoscopic surgery in the
study,19–21, 23, 24, 27, 33, 35, 37, 39, 40 ten studies included only
open liver surgery patients,2, 18, 25, 26, 30–32, 34, 41, 42 five
studies included only laparoscopic surgery patients,22, 28, 29,
36, 38 whilst one study performed a separate analysis for lapa-
roscopic surgery and open surgery.21 A detailed characteristic
of included studies is shown in Table 1.
Sensitivity Analysis and Publication Bias
Funnel plots for overall complication and readmission rates
were used to assess publication bias (Figs. 3 and 4). The asym-
metry of the funnel plots suggested no evidence of publication
bias. Where there was evidence of heterogeneity, a sensitivity
analysis was performed to test the reliability of the results.
Hospital Cost
Twelve studies provided data on hospital cost (1606 patients).
Five of the studies reported hospital cost in US dollar,21, 22, 29,
35, 41 three in Chinese yuan28, 30, 42 and two in euros.24, 33 One
study reported 30% reduction in hospital cost in ERAS group
without providing further data,36 and one did not provide data
on overall hospital cost.34 These two studies were therefore
excluded from the meta-analysis.
A 40·7% reduction in laboratory-associated costs ($333),
54·1% in pharmacy-related costs ($332; p < 0·001), 21·5% in
medical supply costs ($394; p = 0·007) and significant reduc-
tion in therapy-related costs (p < 0·001) were reported in the
ERAS group, with no differences between the two groups in
operating room or radiology costs. One study reported the hos-
pital cost in mean without standard deviation.30 Using a meth-
od suggested by Furukawa et al.,44 standard deviation was
borrowed from a study with similar sample size and mean.41
Pooling of all results revealed a lower hospital cost in ERAS
group compared to standard care (SMD= −0.98; CI, −1.37 to –
0.58; p < 0.0001). However, there was a significant heterogene-
ity observed among all studies (χ2 = 109.63; df = 9; p < 0.0001;
I2 = 92%). In the subgroup analysis for the type of studies, hos-
pital cost was significantly lower in the ERAS group for both
RCTs (SMD= −0.68; CI, −1.02 to –0.33; p < 0.0001) and co-
hort studies (SMD= −1.17.; CI, −1.80 to –0.54; p < 0.0003).
There was no significant difference in the overall hospital costs
between the RCTs and cohort studies (χ2 = 1.82; df = 1;
p < 0.18; I2 = 45%) (Fig. 5). Further subgroup analysis for the
type of surgical approach confirmed a significant hospital cost
savings for both open surgery (SMD= 2.11; CI, 2.42 to −1.80;
p < 0.00001) and laparoscopic surgery (SMD= 0.67; CI, −1.17
to −0.17; p = 0.008) in the ERAS group over standard care.
However, there was a significant difference in the overall hos-
pital costs between the two surgical approaches (χ2 = 22.94,
df = 1 (p < 0.00001), I2 = 95.6%) (Fig. 6).
Length of Hospital Stay
All the studies reported total length of hospital stay. Pooling
the results, LOS was significantly shorter in ERAS group
compared to standard care (MD = −2.22; CI, −2.77 to –1.68;
p < 0.00001), with a significant heterogeneity observed in the
studies (χ2 = 1262.62; df = 26; p < 0.00001; I2 = 98%). A sub-
group analysis for RCT (MD = −3.18; CI, −3.97 to −2.38;
p < 0.00001) and cohort studies (MD = −1.88; CI, −2.43 to
−1.33; p < 0.00001) demonstrated a significant shorter LOS
in the ERAS vs standard care group. However, there was a
significant difference in overall LOS between RCTs and co-
hort studies (χ2 = 6.69; df = 1; p < 0.008; I2 = 85.6%) (Fig. 7).
Further subgroup analysis for the type of surgical approach
found a significant reduction in LOS for both open surgery
(MD = −2.24; CI, −3.33 to −1.15; p < 0.0001) and laparoscop-
ic surgery (MD = −2.77; CI, −3.85 to −1.69, p < 0.00001) in
the ERAS group over standard care. There was no significant
difference in overall LOS between open surgery and laparo-
scopic approach (χ2 = 0.46, df = 1 (p = 0.50), I2 = 0%)
(Fig. 8).
Complication Rates
Twenty-six studies (3496 patients) reported overall complica-
tion rates, with a total of 1332 patients experiencing compli-
cations (507 in ERAS group and 825 in standard care group).
One study did not provide data on the number of cases of
complication34 and was excluded from the meta-analysis.
Pooling the results, there was a significant difference in
overall complication rates between the ERAS group and
the standard care group (RR, 0.71; 95% CI, 0.65–0.77;
p = < 0.00001) but with a significant heterogeneity ob-
served in the studies (χ2 = 52.50; df = 24; p = 0.0007; I2 =
54%). In the subgroup analysis, cases of overall complica-
tions were significantly less among the ERAS group than
standard care in the RCTs (RR, 0.58; 95% CI, 0.48–0. 72;
p = < 0.00001), cohort studies (RR, 0.75; 95% CI, 0.68–
0.82; p = < 0.00001). There was a significant difference
between RCTs and cohort studies (χ2 = 4.59; df = 1; p =
0.03; I2 = 78.2) (Fig. 9). Further subgroup analysis for the
type of surgical approach revealed fewer complication
rates in the ERAS group compared to standard care for
laparoscopic surgery (MD = 0.76; CI, 0.64 to 0.91; p =
0.003). However, complication rates in ERAS group and
standard care were similar for open surgery (MD = 0.86;
CI, 0.73 to 1.02; p = 0.08). There was no significant differ-
ence in the overall complication rates between the two
surgical approaches (χ2 = 0.97, df = 1 (p = 0.33), I2 = 0%).
Moreover, Page et al.34 found significant fewer incidence
of postoperative complications in the ERAS group (1% vs
10%; p = 0.036) (Fig. 10).
J Gastrointest Surg
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Readmission Rates
Twenty-one studies reported readmission rates (2878 pa-
tients). A total of 167 patients were readmitted (82 in ERAS
group and 85 in standard care group). Pooling of the results,
there was no significant difference in readmission rates be-
tween ERAS and standard care (RR, 0.94; 95% CI, 0.70–
1.26; p = 0.68), with no significant heterogeneity observed in
the studies (χ2 = 8.73; df = 19; p = 0.96; I2 = 0%). In the sub-
group analysis, there was no significant difference in readmis-
sion rates between ERAS and standard care in both RCTs
(RR, 0.95; 95% CI, 0.51–1.79; p = 0.88) and cohort studies
(RR, 0.94; 95% CI, 0.67–1.30; p = 070). There is no signifi-
cant difference in the overall readmission rates between RCTs
and cohort studies (χ2 = 0.00; df = 1; p = 0.96; I2 = 0%)
(Fig. 11). In a further subgroup analysis for the type of surgical
approach, readmission rates were similar in the ERAS group
and standard care for both open surgery (MD = 0.98; CI, 0.60
to 1.61; p = 0.94) and laparoscopic surgery (MD = 0.80; CI,
0.35 to 1.87; p = 0.61). There was no significant difference in
the overall readmission rates between the two surgical ap-
proaches (χ2 = 0.16, df = 1 (p = 0.69), I2 = 0%) (Fig. 12).
Mortality rates
Twenty-five studies provided data on mortality rates (3433
patients). Of these studies, no mortality occurred in ten.2,
18–20, 24–26, 30, 31, 39 A total of 20 deaths were reported in the
studies (6 in ERAS and 14 in standard care group). Pooling
the results, there was no significant difference in mortality
rates between ERAS group and standard care (RR, 0.67;
95% CI, 0.30–1.49; p = 0.33), and no significant heterogene-
ity observed among the studies (χ2 = 1.72; df = 11; p = 1.00;
I2 = 0%). Subgroup analysis for RCT (RR, 0.98.; 95% CI,
0.06–15.17; p = 0.99) and cohort studies (RR, 0.65; 95% CI,
028. –1.50; p = 0.31) found no difference in the mortality rates
between ERAS group and standard care group. There was no
difference in mortality between the RCTs and cohort studies
(χ2 = 0.08; df = 1; p = 0.78; I2 = 0%) (Fig. 13).
Compliance
Four studies (474 patients) provided data on compliance to
ERAS elements. Three of the four studies measured overall
compliance to ERAS elements.24, 27, 40 Compliance was
higher in the ERAS group across the three studies, ranging
from 65% to 73.8% in the ERAS group and 20% to 48.7% in
the standard group. Jones et al.25 reported 100% compliance
in 18 out of the 19 ERAS elements in the ERAS group com-
pared to 100% in 11 out the 19 ERAS elements in the standard
care group.Ta
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Discussion
This present review investigated the impact of ERAS
programmes in liver surgery. A comprehensive search was
performed resulting in 6 RCTs and 21 cohort studies with a
total of 3739 patients, making this study the largest and most
comprehensive review conducted on this topic to date. In ad-
dition to confirming that ERAS is safe and feasible, reduction
of LOS and readmission rate without an increase in compli-
cations and mortalities in liver surgery,7–14, 45, 46 we extracted
sufficient data to conduct a subgroup analysis in hospital cost
and confirmed a significant reduction in the overall cost fol-
lowing the implementation of ERAS protocol in liver surgery.
Regarding the primary outcome, hospital costs were signif-
icantly lower in ERAS group in every study included in the
meta-analysis (p < 0.0001). Whilst the main objective of
ERAS protocol is not about healthcare cost savings, however,
evident from this review confirms the results from two previ-
ous reviews9, 10 that introduction of ERAS protocol in liver
surgery represents a significant reduction in hospital expenses.
It was also evident that any significant reduction in length of
hospital stay and complication rates was accompanied by sig-
nificant reduction in total hospital expenses following imple-
mentation ERAS programme.
Our findings suggested that LOS was significantly reduced
by 2.22 days in the ERAS group, which is similar to previous
findings of others.8–10, 12–14 However, there was a significant
heterogeneity in the analysis, which could not be eliminated
even after conducting a sensitivity analysis. Moreover, the
significant heterogeneity did not disappear even after two
studies from Liang and associates which included patients less
than 18 years old were removed from the analysis, neither did
removing studies that reportedmedian and range or applying a
fixed model to the analysis eliminated the significant hetero-
geneity. One explanation for this variation could be due to the
variation of the definition of LOS. Some studies measured
total length of hospital stay, whilst others measured postoper-
ative length of hospital stay after surgical intervention.
Another possible reason for the variation was how discharge
criteria were determined. Among the 17 studies that described
discharge criteria ,2, 19, 20, 24–33, 35, 37, 38, 41 it became more
apparent that there was no standardized discharge criteria for
patients after liver surgery. Among all discharge criteria, the
criteria suggested by Van Dam et al. (2008) including normal
or decreasing serum bilirubin, good pain control with oral
analgesia only, tolerance of solid food, no intravenous fluids,
mobile independently or at the preoperative level and willing-
ness to go home appear to be the most widely adopted by other
liver units.
Similar to previous reviews,8–10, 12, 13 our findings again
suggested a reduction in the overall complication rates in
ERAS group compared to standard care, with a significant
heterogeneity in the cohort studies. Contrary to the findings
Fig. 3 Funnel plots for
complication rates
Fig. 4 Funnel plots for readmission rates
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ofWang et al.,10 our results did not demonstrate a reduction in
overall complication rates in open liver surgery. However, it is
worth noting that this current review excluded studies that
combined both minimal invasive and open surgical approach
in the subgroup analysis. We believe that inclusion of these
studies could introduce bias. Furthermore, our findings im-
plied that complications in liver surgery are complex and can-
not be reduced solely by ERAS pathway. Therefore, where
possible, with the right technique and expertise, laparoscopic
approach should be considered along with ERAS protocol to
reduce risk of complications.
Regarding method of assessing complications, eight of the
cohort studies did not use Clavien-Dindo or mentioned the
method by which postoperative complications were
evaluated,2, 18, 20, 31, 34, 36, 39, 42 suggesting Clavien-Dindo
classification is the most common method of reporting and
grading complications in liver surgery.
The cases of mortalities and readmissions were equally
similar in the two groups (p = 0.68 and p = 1.00, respectively).
The reason for this could be explained by the fact that inci-
dents of readmissions and mortalities reported in the studies
were too low in the studies to detect any significant differ-
ences. For example, overall cases of readmissions were
0.06% both in ERAS group and standard care group (82/
1387 and 85/1400, respectively). Similarly, cases of mortality
were very low across the studies, with 6 deaths (6/1605) in
ERAS group and 14 deaths in standard care group (14/1828).
Follow-up was 30 days across the studies with the exemption
of three studies that reported a 90 days follow-up.18, 19, 31
These 3 studies have a combined total of 458 patients (218
ERAS and 240 standard care), with 4 deaths (1 in ERAS
group and 3 in standard care group). Similarly, two studies
reported 90 days readmission.18, 19 There was a 7.64% (11/
144) readmission rates in ERAS group and 8.43% (14/166) in
standard care group, respectively, which is similar to 5.9%
(82/1387) overall average of readmission rates in ERAS group
and 5.86% (82/1400) in standard care group, suggesting that
90 days follow-up may not be necessary.
There were significant variations in the number of elements
utilized in each study. All studies applied 19 items or less with
the exemption of Teixeira et al.40 that implemented the 23
elements as recommended in the current ERAS guidelines.5
Fig. 5 Forest plot of hospital cost, ERAS vs standard care; subgroup (RCT & Cohort studies)
Fig. 6 Forest plot of hospital cost, ERAS vs standard care; subgroup analysis (Open & Lap)
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The reason for this could be that ERAS protocols were imple-
mented in these studies after the current guidelines were
published.5 Elements commonly mentioned in the studies
were preoperative education, no bowel preparation, minimal
Fig. 7 Forest plot of length of hospital stay, ERAS vs standard care; subgroup analysis (RCT & Cohort studies)
Fig. 8 Forest plot of length of hospital stay, ERAS vs standard care; subgroup analysis (Open & Lap)
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pre-op fasting, carbohydrate drinks, avoidance of excessive
intravenous fluids, minimal use of nasogastric tube and ab-
dominal drain, early resumption of normal diet and oral fluids,
early removal of urinary catheter and enforced mobilization.
Elements such as thromboembolism and antibiotic prophylax-
is, short-acting anaesthetic agent, glycaemic control, preven-
tion of postoperative nausea and vomiting and systemic audit
were less commonly applied. There was notable disagreement
on when to remove catheters and drains. For instance, cathe-
ters were removed within 24 h postoperatively in some stud-
ies, whereas it was left for up to postoperative day 3 in other
studies (Table 2). Similarly, administration of oral analgesia
was recommenced within 24 h in some studies, whilst in
others, postoperation day 3 and 4 in one study. It appears that
these decisions were down to surgeon preference rather than
patients’ specific requirements, making the comparison
among the studies impossible. Whether implementation of
ERAS protocol will be successful or not largely depends on
compliance. Conversely, compliance to ERAS elements was
rarely measured in the included studies. Whenever compli-
ance was measured, overall compliance remained was
generally low even in the ERAS group. One way of measuring
and monitoring compliance within ERAS programme is
through systematic audit.5 However, only 18.5% (5/27) of
the included studies reported performing a systematic audit20,
24, 27, 28, 40 to monitor of ERAS elements within the ERAS
programme.
Limitation
One of the key limitations in this study was the presence of
significant heterogeneity in the effect of ERAS protocols on
LOS and hospital cost. The studies included in this review
were conducted in 11 countries across 4 continents (South
America, North America, Europe and Asian). Most of these
countries have difference healthcare system which may have
contributed to the significant heterogeneity observed in the
analyses. One notable example was the wide variation in the
hospital cost reported across the studies. Although, a random
effect was used when there was a significant evidence of het-
erogeneity, there was no guarantee that heterogeneity can be
eliminated impacting on the validity on our results. The
Fig. 9 Forest plot of complication rates, ERAS vs standard care; subgroup analysis (RCT & Cohort studies)
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Fig. 11 Forest plot of readmission rates, ERAS vs standard care; subgroup analysis (RCT & Cohort studies)
Fig. 10 Forest plot of complication rates, ERAS vs standard care; subgroup analysis (Open & Lap)
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Fig. 13 Forest plot of mortality, ERAS vs standard care; subgroup analysis (RCT & Cohort studies)
Fig. 12 Forest plot of readmission rates, ERAS vs standard care; subgroup analysis (Open & Lap)
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majority of studies included in this review were conducted
over a period of time when ERAS protocols were not stan-
dardized or fully established, with a wide variation in the
elements applied in the protocols. Therefore, it is not clear
whether this has introduced bias regarding the exact impact
of ERAS protocols compared to standard care. Similarly, most
of the included studies were based on retrospective data anal-
ysis introducing further bias to this review. Furthermore, the
majority of the cohort studies were low-quality with small and
unequal sample sizes which may lead to confounding bias. A
larger high-quality multicentre and multinational RCTs is rec-
ommended to confirm some of the findings in this review.
Conclusion
Our review concluded that the introduction of ERAS proto-
cols is safe and feasible in hepatectomies, without increasing
mortality and readmission rates, whilst reducing LOS and risk
of complications, and with a significant hospital cost saving.
Laparoscopic approach may be necessary to reduce complica-
tion rates in liver surgery. However, further studies are needed
to investigate overall compliance to ERAS protocols and its
impact on clinical outcomes.
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